A landmark Phase III trial published in The Lancet in December 2025 has provided some of the clearest evidence yet that proton therapy can significantly improve survival rates for certain cancers, shifting the conversation in radiation oncology. The study, led by the University of Texas MD Anderson Cancer Center, enrolled 440 patients with oropharyngeal cancer across 21 proton centers in the U.S. and found a five-year overall survival rate of 90.9% for those treated with proton therapy, compared with 81% for those receiving traditional photon-based radiation therapy.
Proton therapy’s key advantage is its ability to stop at a precise depth within the body, reducing radiation exposure to surrounding healthy tissue. This clinical benefit is now driving new facility investments across the U.S., including a proton center scheduled to open this summer in Boca Raton, Florida. The findings are particularly significant because they address a long-standing question in oncology: how much does collateral radiation exposure matter over a patient’s lifetime? The data suggest it matters a great deal.
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) anticipated this shift. In November 2025, the company acquired Liora Technologies Europe Ltd., now a subsidiary of LIXTE, which developed the electronically controlled LiGHT proton therapy platform. The acquisition positions LIXTE at the intersection of biotechnology and advanced radiation therapy, moving beyond its traditional focus on cancer drug development. The LiGHT platform is designed to make proton therapy more accessible and cost-effective, potentially expanding its use beyond large academic centers.
The MD Anderson trial is the largest randomized Phase III study to compare proton therapy with traditional radiation. By tracking outcomes over five years, it provides robust evidence that the physical advantages of protons translate into real-world survival benefits. For oropharyngeal cancer, a type of head and neck cancer often linked to HPV, the survival gap of nearly 10 percentage points is substantial. This is expected to influence treatment guidelines and reimbursement decisions, further accelerating adoption.
Proton therapy has been available for decades, but its use has been limited by high costs and the need for large, specialized facilities. Newer technologies, such as the LiGHT platform, aim to reduce these barriers. The Boca Raton center is one of several under construction, reflecting growing confidence in the modality’s value. The Lancet study provides the clinical validation needed to justify these investments.
For investors, the implications are clear: companies involved in proton therapy infrastructure and technology stand to benefit as evidence mounts. LIXTE’s early move into this space through the Liora acquisition could prove prescient. The company’s newsroom at ibn.fm/LIXT provides updates on its progress. As more data emerge, the conversation around proton therapy is likely to shift from whether it works to how best to deploy it widely.
